Contact this trialFirst, we need to learn more about you.
AKT Inhibitor
Afuresertib + Paclitaxel for Ovarian Cancer
Recruiting1 awardPhase 2
Bronx, New York
This trial is testing a new cancer drug that works by inhibiting the AKT protein. The drug is being tested in combination with chemotherapy to see if it is effective in treating ovarian cancer that has become resistant to platinum-based drugs. So far, the drug appears to be safe and effective in this small study.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service